Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06424262
Other study ID # CLTD5815
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date May 2026

Study information

Verified date May 2024
Source Cochlear
Contact Cherith Campbell-Bell
Phone +6129428 6555
Email ccampbellbell@cochlear.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date May 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged 18 years or older (at time of consent) - Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss - Meets local candidacy criteria for cochlear implantation - Compromised functional hearing with a hearing aid in the ear to be implanted - Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm - Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation - Candidate is proficient in the language used to assess speech perception performance - Willing and able to provide written informed consent. Exclusion Criteria: - Planned for a partial insertion of the electrode array - Deafness due to lesions of the acoustic nerve or central auditory pathway, affecting either ear - Active middle-ear infection, in the ear to be implanted - Active autoimmune disease, active immunosuppressive therapy, or use of anticoagulants that cannot be discontinued for surgery - Surgery (including grommets), drainage, presence of an unhealed tympanic membrane, pain, or need for oral or topical antibiotics within 6 months prior to randomisation, in the ear to be implanted - Previously reported diagnosis of auditory neuropathy, in either ear - Previously reported diagnosis, in either ear, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops - Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted - Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo-parietal skull fracture or CSF leaks - History of bacterial meningitis - Known allergic reaction or contraindication to dexamethasone or corticosteroids - Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject - Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted - Prior cochlear implantation, in either ear - Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted - Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation - Women who are pregnant or breastfeeding or plan to become pregnant during the investigation - Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator - Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator - Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator - Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate - Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation - Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the Investigator or Sponsor to not impact this investigation) - Subjects recruited at a French site who are not affiliated with social security - Subjects recruited at a French site who are under legal protection.

Study Design


Intervention

Device:
CI622D
A dexamethasone-eluting Slim Straight electrode
CI622
A standard Slim Straight electrode

Locations

Country Name City State
Australia Royal Victorian Eye and Ear Hospital Melbourne E. Victoria
Australia Royal Prince Alfred Hospital Sydney New South Wales
France Centre Hospitalier Universitaire de Lille Lille
France Hôpital Universitaire Pitié-Salpêtrière Paris
France Centre Hospitalier Universitaire Toulouse Toulouse
Germany Universitätsklinikum Freiburg Freiburg Freiburg Im Breisgau
Germany Medizinische Hochschule Hannover Hannover Niedersachsen
United Kingdom Manchester Royal Infirmary Manchester
United Kingdom University of Southampton Southampton

Sponsors (3)

Lead Sponsor Collaborator
Cochlear Avania, QbD Clinical

Countries where clinical trial is conducted

Australia,  France,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean difference in the monopolar 1+2 (MP1+2) impedance between CI622D (Investigational Medical Device) and CI622 (control device) at 3 months post-activation The impedance will be measured across the active electrodes of the implant for each participant. 3 months post-activation
Secondary Proportion of participants who experience an adverse event and the proportion of participants who experience a device deficiency with CI622D and CI622 Adverse events will be recorded as overall, by severity, by relatedness to device or procedure, or by seriousness. Device deficiency will be recorded as overall and by type. Throughout study (12 months)
Secondary Difference in the mean unaided acoustic hearing thresholds pre-operatively, and from activation to post-activation between CI622D and CI622 Unaided acoustic hearing thresholds will be measured pre-operatively, at activation, and 3, 6 and 12 months post-activation. Pre-operative, 0, 3, 6, 12 months post-activation
Secondary Mean within-subject change in word recognition score in the preferred unilateral listening mode in quiet from pre-implantation to post-activation with CI622D Word recognition scores will be measured at pre-implantation and 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D Word recognition scores will be measured at pre-implantation and 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622 Change in word recognition score will be measured from pre-implantation to 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622 Change in word recognition score will be measured from pre-implantation to 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622 Change in sentence recognition score (Matrix test + 10 SNR) will be measured from pre-implantation to 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622 Change in sentence recognition score (Matrix test + 10 SNR) will be measured from pre-implantation to 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Difference in the mean four-point monopolar and nested bipolar trans-impedances and MP1+2 impedances between CI622D and CI622 measured intraoperatively and from activation to post-activation Four-point monopolar and nested bipolar trans-impedances and MP1+2 impedances will be measured intraoperatively, at activation and 3,6,12 months post-activation. Intraoperative, 0, 3, 6, 12 months post-activation
Secondary Difference in the mean estimated sound processor battery life for CI622D compared from activation to post-activation with CI622 The estimated sound processor battery life (hours per day) will be measured at activation, 3, 6, and 12 months-post activation. 0, 3, 6,12 months post-activation
Secondary Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) from pre-implantation to post-activation between CI622D and CI622 Global SSQ12 scores will be measured between pre-implantation to 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
Secondary Difference in mean within-subject changes in global Health Utilities Index III (HUI3) from pre-implantation to post-activation between CI622D and CI622 Global HUI3 scores will be measured between pre-implantation to 3, 6 and 12 months post-activation. Pre-implantation, 3, 6, 12 months post-activation
See also
  Status Clinical Trial Phase
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Not yet recruiting NCT05973669 - MED-EL Remote Care Multi-Center Feasibility Study N/A
Completed NCT04601909 - FX-322 in Adults With Age-Related Sensorineural Hearing Loss Phase 1
Active, not recruiting NCT04479761 - Sensory Integration of Auditory and Visual Cues in Diverse Contexts N/A
Recruiting NCT05043207 - A Study Protocol for the Validation of UAud in a Clinical Setting. N/A
Recruiting NCT04066270 - Inventory of Radiological and Vestibular Function in Cochlear Implant Candidates
Recruiting NCT04070937 - Correlation of Radiological Lesions With Vestibular Function in Patients With Bilateral Vestibulopathy
Completed NCT03512951 - Subjective Evaluation of a Sound Processing Method for Hearing Aids on Auditory Distance Perception N/A
Completed NCT05855005 - Direct-to-Consumer Hearing Aids and Listening Effort N/A
Recruiting NCT05599165 - Speech Perception in Bimodal Hearing N/A
Completed NCT05101083 - Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids N/A
Completed NCT05521308 - Investigating Hearing Aid Frequency Response Curves N/A
Completed NCT05072457 - Benefit of Assistive Listening Device for Lateralization N/A
Recruiting NCT05776459 - Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) Phase 2
Completed NCT05086276 - FX-322 in Adults With Acquired Sensorineural Hearing Loss Phase 2
Recruiting NCT06058767 - Preschool Hearing Screening N/A
Completed NCT05180630 - Sound Quality Comparisons With Different Hearing Aid Couplings and Venting Systems N/A
Completed NCT03613909 - Acceptance of the CP950 Sound Processor N/A
Active, not recruiting NCT03352154 - Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants N/A
Completed NCT04629664 - FX-322 in Adults With Severe Sensorineural Hearing Loss Phase 1